GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Saniona AB (STU:30S) » Definitions » Institutional Ownership

Saniona AB (STU:30S) Institutional Ownership : 2.84% (As of Apr. 27, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Saniona AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Saniona AB's institutional ownership is 2.84%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Saniona AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Saniona AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Saniona AB Institutional Ownership Historical Data

The historical data trend for Saniona AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Saniona AB Institutional Ownership Chart

Saniona AB Historical Data

The historical data trend for Saniona AB can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 1.43 1.43 1.41 1.40 1.39 2.35 2.90 2.83 2.84 2.84

Saniona AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Saniona AB Business Description

Industry
Traded in Other Exchanges
Address
Smedeland 26B, Glostrup, DNK, DK-2600
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219.

Saniona AB Headlines

No Headlines